Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Apr 7;18(2):e100870.
doi: 10.5812/ijem.100870. eCollection 2020 Apr.

LT4 and Slow Release T3 Combination: Optimum Therapy for Hypothyroidism?

Fereidoun Azizi  1 , Atieh Amouzegar  1 , Ladan Mehran  1 , Hengameh Abdi  1
Affiliations
Review

LT4 and Slow Release T3 Combination: Optimum Therapy for Hypothyroidism?

Fereidoun Azizi et al. Int J Endocrinol Metab. .

Abstract

Context: Levothyroxine (LT4) is recommended as replacement therapy for thyroid hormone deficiency. However, some hypothyroid patients receiving LT4 therapy do not feel as well as healthy subjects. This article aimed to review current knowledge regarding LT4 monotherapy versus LT4+LT3 combination therapy and propose future directions regarding LT4+slow release T3 combination treatment for hypothyroidism.

Evidence acquisition: We searched PubMed and Scopus using related keywords.

Results: The LT4 monotherapy causes higher serum free T4 (fT4), subnormal serum free T3 (fT3), and fT3/fT4 ratio in one-fourth of patients. The LT4+LT3 combination therapy increases serum T3 and fT3 concentrations and may normalize the fT3/fT4 ratio. However, the primary outcomes, including thyroid hormone deficiency, anxiety, depression, and quality of life, may not be better in LT4+LT3 combination therapy than in LT4 monotherapy. Recent surveys show that combination therapy is on the rise, in particular, due to patient demand. The LT4 plus slow-release LT3 preparation has shown promising results in improving serum thyroid hormone concentrations.

Conclusions: The beneficial effect of LT4+LT3 combination therapy is not clear, and the safety of long-term therapy is yet under question. More scientific well-designed research projects are required in this field.

Keywords: Hypothyroidism; T3+T4 Combination; Treatment.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interests: There is no conflict of interest.

References

    1. Jonklaas J, Tefera E, Shara N. Prescribing therapy for hypothyroidism: Influence of physician characteristics. Thyroid. 2019;29(1):44–52. doi: 10.1089/thy.2018.0369. - DOI - PMC - PubMed
    1. Burch HB, Burman KD, Cooper DS, Hennessey JV. A 2013 survey of clinical practice patterns in the management of primary hypothyroidism. J Clin Endocrinol Metab. 2014;99(6):2077–85. doi: 10.1210/jc.2014-1046. - DOI - PubMed
    1. Garber JR, Cobin RH, Gharib H, Hennessey JV, Klein I, Mechanick JI, et al. Clinical practice guidelines for hypothyroidism in adults: Cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Thyroid. 2012;22(12):1200–35. doi: 10.1089/thy.2012.0205. - DOI - PubMed
    1. Jonklaas J, Bianco AC, Bauer AJ, Burman KD, Cappola AR, Celi FS, et al. Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement. Thyroid. 2014;24(12):1670–751. doi: 10.1089/thy.2014.0028. - DOI - PMC - PubMed
    1. Michaelsson LF, Medici BB, la Cour JL, Selmer C, Roder M, Perrild H, et al. Treating hypothyroidism with thyroxine/triiodothyronine combination therapy in Denmark: Following guidelines or following trends? Eur Thyroid J. 2015;4(3):174–80. doi: 10.1159/000437262. - DOI - PMC - PubMed

LinkOut - more resources